- Home
- CMMB vs ANVS Comparison
CMMB vs ANVS Comparison
Compare CMMB & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- ANVS
- Stock Information
- Founded
- CMMB 2004
- ANVS 2008
- Country
- CMMB Israel
- ANVS United States
- Employees
- CMMB N/A
- ANVS N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- ANVS Health Care
- Exchange
- CMMB Nasdaq
- ANVS Nasdaq
- Market Cap
- CMMB 23.0M
- ANVS 24.2M
- IPO Year
- CMMB N/A
- ANVS 2020
- Fundamental
- Price
- CMMB $1.32
- ANVS $3.05
- Analyst Decision
- CMMB Strong Buy
- ANVS Strong Buy
- Analyst Count
- CMMB 2
- ANVS 5
- Target Price
- CMMB $8.50
- ANVS $34.75
- AVG Volume (30 Days)
- CMMB 133.3K
- ANVS 575.1K
- Earning Date
- CMMB 05-15-2025
- ANVS 05-13-2025
- Dividend Yield
- CMMB N/A
- ANVS N/A
- EPS Growth
- CMMB N/A
- ANVS N/A
- EPS
- CMMB N/A
- ANVS N/A
- Revenue
- CMMB N/A
- ANVS N/A
- Revenue This Year
- CMMB N/A
- ANVS N/A
- Revenue Next Year
- CMMB N/A
- ANVS N/A
- P/E Ratio
- CMMB N/A
- ANVS N/A
- Revenue Growth
- CMMB N/A
- ANVS N/A
- 52 Week Low
- CMMB $0.78
- ANVS $1.11
- 52 Week High
- CMMB $2.55
- ANVS $17.88
- Technical
- Relative Strength Index (RSI)
- CMMB 50.02
- ANVS 73.94
- Support Level
- CMMB $1.22
- ANVS $1.95
- Resistance Level
- CMMB $1.38
- ANVS $3.48
- Average True Range (ATR)
- CMMB 0.08
- ANVS 0.28
- MACD
- CMMB -0.01
- ANVS 0.11
- Stochastic Oscillator
- CMMB 40.00
- ANVS 76.63
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.